COVID-19 Vaccine study in.....>

GLOBAL MARKET/OPINION: COVID-19 Vaccine study in peer-review journal The Lancet

appears to be quite promising, though as it notes, further research required on

effectiveness. The journal Tweeted today: "NEW Research-First human trial of

COVID19 vaccine finds it is safe and induces rapid immune response: finding from

a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial.

Vaccine candidate was well tolerated at all doses with no serious adverse events

reported within 28 days. Most adverse events were mild or moderate; 83% of those

receiving low & middle doses & 75% in the high dose group reporting at least 1

adverse reaction within 7 days. Study of 108 adults finds vaccine produced

neutralising antibodies and T-cell response against SARS-CoV-2, but further

research is needed to confirm whether the vaccine protects against SARSCoV2

infection"